TrialCancer2016

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.

Koichi Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.